Cardiac surgery in patients on antiplatelet and antithrombotic agents

Semin Thorac Cardiovasc Surg. 2005 Spring;17(1):66-72. doi: 10.1053/j.semtcvs.2005.01.001.

Abstract

The widespread application of antithrombotic agents carries significant potential for inducing excessive peri-operative hemorrhage during cardiac surgery. Specific surgical and medical strategies can be employed to attenuate this bleeding. These antithrombotic agents and anti-hemorrhagic measures will be reviewed in depth.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Aged
  • Blood Loss, Surgical / prevention & control*
  • Cardiac Surgical Procedures / adverse effects
  • Cardiac Surgical Procedures / methods
  • Cardiovascular Diseases / diagnosis
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / mortality
  • Cardiovascular Diseases / surgery*
  • Coronary Artery Bypass / adverse effects
  • Coronary Artery Bypass / methods
  • Coronary Disease / diagnosis
  • Coronary Disease / mortality
  • Coronary Disease / surgery
  • Dose-Response Relationship, Drug
  • Female
  • Fibrinolytic Agents / adverse effects*
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / adverse effects*
  • Platelet Aggregation Inhibitors / therapeutic use
  • Postoperative Hemorrhage / epidemiology
  • Postoperative Hemorrhage / etiology*
  • Prognosis
  • Risk Assessment
  • Survival Rate
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors